27832159|t|A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet -Induced Obese C57BL/6J Mice
27832159|a|Obesity is now recognized as a state of chronic low-grade inflammation and is called as metabolic inflammation. Delta-5 desaturase (D5D) is an enzyme that metabolizes dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA). Thus, D5D inhibition increases DGLA (precursor to anti-inflammatory eicosanoids) while decreasing AA (precursor to pro-inflammatory eicosanoids), and could result in synergistic improvement in the low-grade inflammatory state. Here, we demonstrate reduced insulin resistance and the anti-obesity effect of a D5D selective inhibitor (compound-326), an orally active small-molecule, in a high-fat diet -induced obese (DIO) mouse model. In vivo D5D inhibition was confirmed by determining changes in blood AA / DGLA profiles. In DIO mice, chronic treatment with compound-326 lowered insulin resistance and caused body weight loss without significant impact on cumulative calorie intake. Decreased macrophage infiltration into adipose tissue was expected from mRNA analysis. Increased daily energy expenditure was also observed following administration of compound-326, in line with sustained body weight loss. These data indicate that the novel D5D selective inhibitor, compound-326, will be a new class of drug for the treatment of obese and diabetic patients.
27832159	18	27	Inhibitor	T121	C0014432
27832159	31	49	Delta-5 Desaturase	T116,T126	C0057338
27832159	57	75	Insulin Resistance	T046	C0021655
27832159	80	99	Reduces Body Weight	T033	C1262477
27832159	103	107	Diet	T168	C0012155
27832159	117	122	Obese	T047	C0028754
27832159	123	136	C57BL/6J Mice	T015	C1521751
27832159	137	144	Obesity	T047	C0028754
27832159	195	207	inflammation	T046	C0021368
27832159	225	234	metabolic	T169	C0311400
27832159	235	247	inflammation	T046	C0021368
27832159	249	267	Delta-5 desaturase	T116,T126	C0057338
27832159	269	272	D5D	T116,T126	C0057338
27832159	280	286	enzyme	T116,T126	C0014442
27832159	304	327	dihomo-γ-linolenic acid	T109	C0000658
27832159	329	333	DGLA	T109	C0000658
27832159	338	354	arachidonic acid	T109	C0003695
27832159	356	358	AA	T109	C0003695
27832159	367	370	D5D	T116,T126	C0057338
27832159	371	381	inhibition	T039	C1524081
27832159	392	396	DGLA	T109	C0000658
27832159	411	428	anti-inflammatory	T080	C1515999
27832159	429	440	eicosanoids	T109	C0013725
27832159	459	461	AA	T109	C0003695
27832159	493	504	eicosanoids	T109	C0013725
27832159	527	538	synergistic	T080	C2986495
27832159	539	550	improvement	T077	C2986411
27832159	609	616	reduced	T080	C0392756
27832159	617	635	insulin resistance	T046	C0021655
27832159	644	656	anti-obesity	T121	C0376607
27832159	669	672	D5D	T116,T126	C0057338
27832159	694	706	compound-326	T121	C1254351
27832159	712	718	orally	T082	C0442027
27832159	726	740	small-molecule	T109	C1328819
27832159	747	760	high-fat diet	T168	C0453819
27832159	770	787	obese (DIO) mouse	T015	C0025933
27832159	788	793	model	T050	C0012644
27832159	803	806	D5D	T116,T126	C0057338
27832159	807	817	inhibition	T039	C1524081
27832159	858	863	blood	T031	C0005767
27832159	864	866	AA	T109	C0003695
27832159	869	873	DGLA	T109	C0000658
27832159	874	882	profiles	T059	C2022317
27832159	887	895	DIO mice	T015	C0025933
27832159	920	932	compound-326	T121	C1254351
27832159	941	959	insulin resistance	T046	C0021655
27832159	971	987	body weight loss	T033	C1262477
27832159	1029	1043	calorie intake	T081	C4281687
27832159	1055	1098	macrophage infiltration into adipose tissue	T033	C4014887
27832159	1117	1130	mRNA analysis	T059,T062	C0872262
27832159	1148	1166	energy expenditure	T039	C0014272
27832159	1195	1209	administration	T061	C1533734
27832159	1213	1225	compound-326	T121	C1254351
27832159	1250	1266	body weight loss	T033	C1262477
27832159	1303	1306	D5D	T116,T126	C0057338
27832159	1317	1326	inhibitor	T121	C0014432
27832159	1328	1340	compound-326	T121	C1254351
27832159	1391	1396	obese	T047	C0028754
27832159	1401	1409	diabetic	T047	C0011847
27832159	1410	1418	patients	T101	C0030705